Acute myocardial infarction is one of the leading causes of mortality in Argentina. In ST-segment elevation acute myocardial infarction, the total duration of ischemia is crucial in determining the prognosis, as ‘time is myocardium’. Technological advances have reduced ischemic times worldwide, which has been associated with a decrease in mortality. In Argentina, the ARGENIAM-ST registry is the only national registry of ST-segment elevation myocardial infarction with 10 years of follow-up. (1) The best way to monitor this condition is through such registries, which reflect real-world care, thereby enabling the planning of health policies and the evaluation of their outcomes.
The national effectiveness in terms of reperfusion therapy is noteworthy, with door-to-reperfusion times similar to those in international registries and reperfusion rates exceeding 90% in 8 of the 10 years of the study.
However, our main weakness, as evidenced by the registry, lies in the prolonged time from the onset of symptoms to presentation, which could explain the lack of decline in mortality over these 10 years compared with registries from other countries. (2,3) The average symptom-presentation time is 120 minutes, significantly longer than that reported in registries such as the Spanish registry, which is approximately 60 minutes. (4)
It is essential to improve public education on recognizing symptoms consistent with myocardial infarction and to implement national strategies to optimize patient referral to achieve early reperfusion.
It is worth noting the decline in patient enrolment over the years. A limitation of these registries is their representativeness. Given that participation is voluntary, they tend to reflect the practice of institutions with greater academic motivation-generally those with higher patient volumes, which are the ones that sustain the registry over time. (5) It is essential to reinforce the importance of maintaining and expanding these registries within the medical community to promote more equitable and effective health policies.
The lack of reduction in the mortality rate over these 10 years, despite the therapeutic advances, is discouraging; yet there is still hope that the healthcare system will improve, ensuring universal access and reducing delays. This will help to achieve a mortality rate from acute myocardial infarction similar to that seen in international registries.
Ethical considerations
Not applicable.
Conflicts of interest
None declared.
(See authors' conflict of interests forms on the web).
